Treatment period 1 | Treatment period 2 | Treatment period 3 | |||||||
---|---|---|---|---|---|---|---|---|---|
Pradigastat 20 mg (n = 6) | Pradigastat 40 mg (n = 6) | Pradigastat 10 mg (n = 4) | |||||||
Baseline | EOT | % Change | Baseline | EOT | % Change | Baseline | EOT | % Change | |
CM-TG | 22.11. (7.51) | 8.95. (1.86) | −59.5% | 51.97. (49.78) | 12.64. (7.12) | −75.7% | 52.90. (10.11) | 30.93. (13.48) | −41.5% |
CM-C | 5.38. (2.20) | 3.32. (0.89) | −38.3% | 9.50. (6.28) | 4.38. (3.23) | −53.9% | 8.48. (2.91) | 6.45. (3.46) | −23.9% |
LDL-TG | 0.65. (0.22) | 0.55. (0.21) | −15.4% | 1.33. (2.19) | 0.36. (0.17) | −72.9% | 0.65 (0.17) | 0.50. (0.29) | −23.1% |
LDL-C | 0.99. (0.34) | 1.10. (0.25) | 11.1% | 1.01. (0.40) | 1.02. (0.26) | 1.0% | 0.93. (0.39) | 0.79 (0.19) | −15.1% |
HDL-TG | 0.25. (0.1) | 0.27. (0.1) | 8.0% | 0.25. (0.10) | 0.22. (0.04) | −12.0% | 0.20. (0.08) | 0.25. (0.06) | 25.0% |
HDL-C | 0.34. (0.12) | 0.55. (0.09) | 61.7% | 0.14. (0.13) | 0.46. (0.11) | 228.6% | 0.17. (0.21) | 0.25. (0.14) | 47.1% |
VLDL-TG | 2.75. (0.24) | 2.40. (0.45) | −12.7% | 2.52. (1.45) | 3.06. (0.75) | 21.4% | 3.55. (1.53) | 3.53. (1.62) | −0.6% |
VLDL-C | 1.10. (0.56) | 1.08. (0.28) | −1.8% | 0.51. (0.59) | 1.40. (0.55) | 63.6% | 0.23. (0.25) | 0.94. (0.45) | 308.7% |